UPR1024

UPR1024 or its derivatives might serve as drugs for the treatment of lung cancer in patients resistant to classic tyrosine kinase inhibitors; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Alfieri, Roberta R: 1 article (02/2008)
2.	Bonelli, Mara: 1 article (02/2008)
3.	Bordi, Fabrizio: 1 article (02/2008)
4.	Carmi, Caterina: 1 article (02/2008)
5.	Cavazzoni, Andrea: 1 article (02/2008)
6.	Frazzi, Raffaele: 1 article (02/2008)
7.	Fumarola, Claudia: 1 article (02/2008)
8.	Galetti, Maricla: 1 article (02/2008)
9.	Lodola, Alessio: 1 article (02/2008)
10.	Mor, Marco: 1 article (02/2008)

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 02/01/2008 - "Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines." 02/01/2008 - "UPR1024 or its derivatives might serve as a basis for development of drugs for the treatment of lung cancer in patients resistant to classic tyrosine kinase inhibitors."

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors